Variant classification in precision oncology
- 22 April 2019
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 145 (11) , 2996-3010
Abstract
Next‐generation sequencing has become a cornerstone of therapy guidance in cancer precision medicine and an indispensable research tool in translational oncology. Its rapidly increasing use during the last decade has expanded the options for targeted tumor therapies, and molecular tumor boards have grown accordingly. However, with increasing detection of genetic alterations, their interpretation has become more complex and error‐prone, potentially introducing biases and reducing benefits in clinical practice. To facilitate interdisciplinary discussions of genetic alterations for treatment stratification between pathologists, oncologists, bioinformaticians, genetic counselors and medical scientists in specialized molecular tumor boards, several systems for the classification of variants detected by large‐scale sequencing have been proposed. We review three recent and commonly applied classifications and discuss their individual strengths and weaknesses. Comparison of the classifications underlines the need for a clinically useful and universally applicable variant reporting system, which will be instrumental for efficient decision making based on sequencing analysis in oncology. Integrating these data, we propose a generalizable classification concept featuring a conservative and a more progressive scheme, which can be readily applied in a clinical setting.Keywords
This publication has 98 references indexed in Scilit:
- LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug PhenforminCancer Cell, 2013
- Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumorsMedical Oncology, 2013
- Activating Mutations in ERBB2 and Their Impact on Diagnostics and TreatmentFrontiers in Oncology, 2013
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1Proceedings of the National Academy of Sciences, 2012
- Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot StudyScience Translational Medicine, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- The DNA Damage Response: Making It Safe to Play with KnivesMolecular Cell, 2010
- Rapid-Learning System for Cancer CareJournal of Clinical Oncology, 2010
- Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test resultsHuman Mutation, 2008
- DNA‐damage repair; the good, the bad, and the uglyThe EMBO Journal, 2008